Publication: Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care
| dc.contributor.author | Valencia, Jorge | |
| dc.contributor.author | Lazarus, Jeffrey V | |
| dc.contributor.author | Ceballos, Francisco C | |
| dc.contributor.author | Troya, Jesús | |
| dc.contributor.author | Cuevas, Guillermo | |
| dc.contributor.author | Resino, Salvador | |
| dc.contributor.author | Torres-Macho, Juan | |
| dc.contributor.author | Ryan, Pablo | |
| dc.contributor.funder | Gilead Sciences (Spain) | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | AbbVie | |
| dc.contributor.funder | Asociación Española para Estudio del Higado (AEEH) | es_ES |
| dc.contributor.funder | Madrid Positivo Association | es_ES |
| dc.date.accessioned | 2024-05-22T08:54:43Z | |
| dc.date.available | 2024-05-22T08:54:43Z | |
| dc.date.issued | 2022-02 | |
| dc.description.abstract | Background and aims: People who inject drugs (PWID) and other marginalized populations with high hepatitis C virus (HCV) infection rates represent a unique challenge for treatment initiation due to health, administrative and social barriers. We analysed the HCV cascade of care (CoC) in some vulnerable subpopulations in Madrid, Spain, when using a mobile point-of-care (PoC). Methods: From 2019 to 2021, a mobile unit was used to screen active HCV using a linkage-to-care and two-step PoC-based strategy. Viremic participants were grouped into four subgroups: PWID, homeless individuals and people with a mental health disorder (MHD) and alcohol use disorder (AUD). Logistic regression, and Cox and Aalen's additive models were used to analyse associated factors and differences between groups. Results: A prospectively recruited cohort of 214 HCV-infected individuals (73 PWID, 141 homeless, 57 with a MHD and 91 with AUD) participated in the study. The overall HCV CoC analysis found that 178 (83.1%) attended a hospital, 164 (76.6%) initiated direct-acting antiviral therapy and 141 (65.8%) completed therapy, of which 99 (95.2%) achieved sustained virological response (SVR). PWID were significantly less likely to initiate treatment, whereas individuals with AUD waited longer before starting the treatment. Both people with AUD and PWID were significantly less likely to complete HCV treatment. Conclusions: Overall, SVR was achieved in the majority of the participants treated. However, PWID need better linkage to care and treatment, whereas PWID and AUD need more support for treatment completion. | es_ES |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | This work was funded by a research grant from Gilead Sciences (CHIME program, IN-ES-987-5391) and Instituto de Salud Carlos III (ISCIII; grant numbers PI20CIII/00004 and RD16CIII/0002/0002 to SR). This work was also funded by AbbVie, Asociación Española para el Estudio del Hígado (AEEH) and Madrid Positivo Association. The funders had no role in the study design, datac ollection, analysis, decision to publish or preparation of the manuscript | es_ES |
| dc.format.number | 2 | es_ES |
| dc.format.page | 309-319 | es_ES |
| dc.format.volume | 42 | es_ES |
| dc.identifier.citation | Liver Int. 2022 Feb;42(2):309-319. | es_ES |
| dc.identifier.doi | 10.1111/liv.15095 | es_ES |
| dc.identifier.e-issn | 1478-3231 | es_ES |
| dc.identifier.journal | Liver international : official journal of the International Association for the Study of the Liver | es_ES |
| dc.identifier.pubmedID | 34767680 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/19519 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | Wiley | |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RD16CIII/0002/0002 | es_ES |
| dc.relation.publisherversion | https://doi.org/10.1111/liv.15095 | es_ES |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
| dc.repisalud.institucion | ISCIII | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Cascade of care | es_ES |
| dc.subject | Hepatitis C virus | es_ES |
| dc.subject | Marginalized populations | es_ES |
| dc.subject | Model of care | es_ES |
| dc.subject | Point-of-care test | es_ES |
| dc.subject.mesh | Hepatitis C | es_ES |
| dc.subject.mesh | Hepatitis C, Chronic | es_ES |
| dc.subject.mesh | Substance Abuse, Intravenous | es_ES |
| dc.subject.mesh | Antiviral Agents | es_ES |
| dc.subject.mesh | Hepacivirus | es_ES |
| dc.subject.mesh | Humans | es_ES |
| dc.subject.mesh | Point-of-Care Systems | es_ES |
| dc.title | Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care | es_ES |
| dc.type | research article | es_ES |
| dc.type.hasVersion | SMUR | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 8741bd82-84d2-486a-a71c-90cc78f61ed5 | |
| relation.isAuthorOfPublication | 89b17350-14e3-4dfd-b797-6ee6ca5363b8 | |
| relation.isAuthorOfPublication.latestForDiscovery | 8741bd82-84d2-486a-a71c-90cc78f61ed5 | |
| relation.isFunderOfPublication | e30731f7-32c2-43af-b658-fe28964bc958 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | ffb8e2d3-a3e4-4345-ade9-736e37d36399 | |
| relation.isFunderOfPublication.latestForDiscovery | e30731f7-32c2-43af-b658-fe28964bc958 | |
| relation.isPublisherOfPublication | d81e762a-95f7-4917-88a1-8004b3b8caa7 | |
| relation.isPublisherOfPublication.latestForDiscovery | d81e762a-95f7-4917-88a1-8004b3b8caa7 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- DifferencesHepatitis_C_VirusCascadeCare_2022.pdf
- Size:
- 1.56 MB
- Format:
- Adobe Portable Document Format
- Description:


